Suicide Risk in Cancer Patients From 1960 to 1999

2004 ◽  
Vol 22 (20) ◽  
pp. 4209-4216 ◽  
Author(s):  
Erlend Hem ◽  
Jon H. Loge ◽  
Tor Haldorsen ◽  
Øivind Ekeberg
Keyword(s):  
Relative Risk ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Suicide Risk ◽  
International Classification Of Diseases ◽  
Patients With Cancer ◽  
Classification Of Diseases ◽  
Cancer Types ◽  
Male Patients ◽  
Standardized Mortality Ratios

Purpose Suicide risk is reportedly higher for cancer patients than for the general population, but estimates vary and analyses of trends are few. The aim of the present study was to determine whether cancer patients had a higher suicide risk between 1960 and 1999. Patients and Methods A cohort comprising patients from the Cancer Registry of Norway 1960 to 1997 was linked to suicide diagnosis in the Register of Deaths at Statistics Norway and observed during 1960 to 1999. The cohort consisted of all cancer patients registered in the Cancer Registry of Norway 1960 to 1997 (N = 490,245 patients with 520,823 cancer diagnoses). Suicide was defined according to death certificates based on the International Classification of Diseases (versions 7, 8, 9, and 10). Results During the period, 589 cancer patients (407 males and 182 females) committed suicide. The relative risk was elevated for males and females, with standardized mortality ratios (SMRs) of 1.55 (95% CI, 1.41 to 1.71) and 1.35 (95% CI, 1.17 to 1.56), respectively. Risk was highest in the first months after diagnosis. For both sexes, there was a significant decrease in the relative suicide risk over decades. The risk was markedly increased among male patients with cancer of respiratory organs (SMR, 4.08; 95% CI, 2.96 to 5.47). Otherwise, the SMRs varied from 0.76 to 3.67 across cancer types. Conclusion Cancer may be a risk factor for suicide, particularly shortly after diagnosis. However, the relative risk gradually decreased during the period 1960 to 1999.

National trends in opioid-related hospitalizations among patients with cancer.

2018 ◽  
Vol 36 (34_suppl) ◽  
pp. 199-199
Author(s):  
Isaac S. Chua ◽  
Richard Leiter ◽  
Kate T. Brizzi ◽  
Charles A. Coey ◽  
Emanuele Mazzola ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Temporal Trends ◽  
International Classification Of Diseases ◽  
Cross Sectional Study ◽  
Primary Diagnosis ◽  
Cross Sectional ◽  
Patients With Cancer ◽  
Younger Age ◽  
Classification Of Diseases ◽  
National Trends

199 Background: Cancer patients are routinely prescribed opioids for cancer-related pain. With recent attention to the opioid epidemic, we sought to identify risk factors and to describe the incidence of opioid-related hospitalizations among cancer patients. Methods: Serial cross-sectional study of adult cancer patients with opioid-related hospitalizations using the National Inpatient Sample (NIS) database from January 2006 to December 2014. We identified cancer patients using the International Classification of Diseases, Ninth Revision (ICD-9) codes. We defined opioid-related hospitalizations as ICD-9 codes for heroin poisoning, opioid poisoning, or opioid dependence or abuse in the primary diagnosis field. A logistic regression model identified predictors for opioid-related hospitalizations. We adjusted temporal trends for opioid-related hospitalizations for all-cause hospitalizations among cancer patients. Results: Among 25,443,362 hospitalizations for cancer patients, there were 14,336 opioid-related hospitalizations. Non-heroin opioid poisoning made up 88% of opioid-related hospitalizations. Predictors for opioid-related hospitalizations for cancer patients included drug abuse (OR 9.40, 95% CI 8.28 - 10.66), younger age [age 18 - 29 (OR 4.00, 95% CI 3.10 - 5.17); age 30 - 49 (OR 3.99, 95% CI 3.43 - 4.65)], depression (OR 2.17, 95% CI 1.97 - 2.39), alcohol abuse (OR 1.21, 95% CI 1.03 - 1.41), and year of hospitalization [2009-2011 (OR 1.19; 95% CI 1.07 - 1.32); 2012 - 2014 (OR 1.19; 95% CI, 1.06 - 1.32)]. On average, opioid-related hospitalizations increased by 0.003% per year (p = 0.002). Conclusions: Opioid-related hospitalizations among cancer patients are rare, appear to be increasing over time, and are largely due to non-heroin opioid poisoning. Standardized opioid risk screening based on validated predictors may identify cancer patients with the greatest risk of an opioid-related hospitalization.

scholarly journals Use of Anti-angiogenic Drugs Potentially Associated With an Increase on Serum AST, LDH, CK, and CK-MB Activities in Patients With Cancer: A Retrospective Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Qi Zheng ◽  
Hanzhou Wang ◽  
Wei Hou ◽  
Ying Zhang
Keyword(s):  
Creatine Kinase ◽  
Cancer Patients ◽  
Muscle Injury ◽  
Lactic Dehydrogenase ◽  
Cardiovascular Risks ◽  
Patients With Cancer ◽  
Specific Effects ◽  
Before And After ◽  
Cancer Types ◽  
Myocardial Muscle

Background: There is a large amount of evidence that anti-angiogenic drugs are effective safe. However, few studies have evaluated the specific effects of anti-angiogenic drugs on myocardial enzyme injury biomarkers: aspartate aminotransferase (AST), lactic dehydrogenase (LDH), creatine kinase (CK) and creatine kinase isoenzyme (CK-MB). The purpose of our study was to determine whether anti-angiogenic drugs serum AST, LDH, CK, and CK-MB activities of cancer patients treated with anti-angiogenic drugs.Methods: This study retrospectively analyzed 81 cancer patients. Patients who had used anti-angiogenic drugs were selected. Serum AST, LDH, CK, and CK-MB activities were measured before and after treatment with anti-angiogenic drugs for 3 weeks.Results: A total of 16 cancer types were analyzed. The distribution of the cancer types in the patients was mainly concentrated in lung, gastric, and colorectal cancers. The anti-angiogenic treatment markedly increased AST, LDH, CK, and CK-MB activities by 32.51, 7.29, 31.25, and 55.56%, respectively in serum.Conclusions: Our findings suggest that patients, who had used anti-angiogenic drugs were likely to have elevated AST, LDH, and CK, indicators of myocardial muscle injury. Use of anti-angiogenic drugs should not be assumed to be completely safe and without any cardiovascular risks.

scholarly journals Cancer Epidemiology Based on Hospital-Based Cancer Registry at National Referral Hospital of Indonesia, 2013

2021 ◽  
Vol 9 (1) ◽  
pp. 36
Author(s):  
Soehartati Gondhowiardjo
Keyword(s):  
Cancer Patients ◽  
Cancer Registry ◽  
Histopathological Examination ◽  
Lymphoblastic Leukemia ◽  
Locally Advanced ◽  
Nasopharyngeal Cancer ◽  
Epidemiological Data ◽  
Hospital Policy ◽  
Duct Carcinoma ◽  
Male Patients

Cancer is the primary cause of death in developed or developing country. To develop hospital policy and research, comprehensive epidemiological data are needed. This research aims to provide epidemiological and demographical profiles of cancer from a hospital-based cancer registry (HBCR) at Cipto Mangunkusumo Hospital in 2013. This is a descriptive study involving cancer patients based on the HBCR from January-December 2013. Cancer frequency at the hospital in 2013 was 4,915 cases, with the majority of the patients were 45-54 years old, regardless of their sexes. Sex ratio was 3:2 for women and men, respectively. The most frequent age of female patients was 45-54 years old, while for male patients was 55-64 years old. In 2013, the hospital served more cancer patients from outside Jakarta than from Jakarta itself. Breast cancer, cervical cancer, and hematopoietic and reticuloendothelial systems cancer were the most prevalent types of cancer in women. Additionally, hematopoietic and reticuloendothelial systems cancer, nasopharyngeal cancer, and lymphoma were the most prevalent types of cancer in men. Most breast and cervical cancers came in either locally advanced or advanced stage. Histopathological examination revealed that most prevalent types of cancer were Infiltrating duct carcinoma of breast, nonkeratinized squamous cell carcinoma of cervix, and acute lymphoblastic leukemia. Keywords: hospital-based cancer registry, epidemiology, histopathology, staging, demography.   Epidemiologi Kanker Berdasarkan Registrasi Kanker Berbasis Rumah Sakit di Pusat Rujukan Nasional Indonesia, 2013 Abstrak Kanker merupakan penyebab kematian utama pada negara maju maupun berkembang. Untuk menentukan arah kebijakan rumah sakit dan penelitian, diperlukan data komprehensif mengenai epidemiologi kanker. Penelitian ini bertujuan untuk memberikan gambaran profil epidemiologi dan demografi kanker di Rumah Sakit Cipto Mangunkusumo berdasarkan Registrasi Kanker Berbasis Rumah Sakit (HBCR) tahun 2013. Studi ini menggunakan desain deskriptif yang melibatkan semua pasien kanker berdasarkan data HBCR. pada Januari-Desember 2013. Frekuensi kanker di RSCM pada tahun 2013 adalah 4,915 kasus, dengan mayoritas pasien berusia 45-54 tahun, baik jenis kelamin wanita ataupun pria. Rasio jenis kelamin perempuan dibandingkan laki-laki adalah 3:2. Rentang usia paling sering pada pasien wanita adalah 45-54 tahun, sedangkan pada laki-laki adalah 55-64 tahun. Pada tahun 2013, RSCM lebih banyak melayani pasien kanker dari luar Jakarta dibandingkan dari Jakarta. Kanker payudara,serviks dan kanker darah dan sistem retikuloendotel merupakan jenis kanker tersering pada perempuan. Sebagai tambahan, kanker darah dan sistem retikuloendotel, nasofaring dan kegasanan kelenjar getah bening (limfoma) merupakan kanker tersering pada laki-laki. Sebagian besar kanker payudara dan serviks datang dengan stadium lokal lanjut atau lanjut. Pemeriksaan histopatologi menunjukkan bahwa tipe patologi kanker tersering adalah karsinoma duktal invasif pada kanker payudara, karsinoma sel skuamosa tidak berkeratin pada kanker serviks, dan leukemia limfoblastik akut. Kata kunci: Registrasi kanker berbasis rumah sakit, epidemiologi, histopatologi, stadium, demografi.

scholarly journals Spatial analysis of road traffic accident deaths in the state of Paraná, 2007-2016

2021 ◽  
Vol 10 (11) ◽  
pp. e431101119942
Author(s):  
Claudia Schneck ◽  
Elias Teixeira Krainski ◽  
Carlos Eduardo da Rocha Omoto ◽  
Daniel Grabasky Accioly ◽  
Faissal Nemer Hajar ◽  
...  
Keyword(s):  
Relative Risk ◽  
Spatial Analysis ◽  
Road Traffic Accident ◽  
Traffic Accident ◽  
Traffic Accidents ◽  
Road Traffic ◽  
International Classification Of Diseases ◽  
The State ◽  
Classification Of Diseases ◽  
Icd 10

Brazil is in fifth place among countries with the highest number of land transport accidents. The state of Paraná, Brazil, was the object of this study which conducted spatial analysis with the aim of identifying areas where this phenomenon occurs more and their time series over a 10-year period. This was an ecological and exploratory observational study covering the period 2007 to 2016 in 39 micro-regions of the state of Paraná. Data of road traffic accident deaths as per the International Classification of Diseases (ICD-10, codes V01 to V89) held on the Mortality Information System, were analyzed. Relative risk rates were calculated and choropleth maps were built. A total of 31,651 deaths from the causes examined were recorded according to municipality of occurrence. The most frequent ICD-10 items found were those involving automobile occupants, motorcyclists, pedestrians and cyclists in road traffic accidents. An overall falling trend was found with effect from 2012. The rate by area did not show pronounced spatial dependence and there was considerable variation, whereby the Cerro Azul micro-region had the lowest relative risk in the period, while in Campo Mourão deaths were around 53.3% above the expected level. The estimated average annual trend for the Curitiba micro-region had the steepest fall in the period, while Campo Mourão had the highest rising trend. The trend analysis indicated places where more robust public policy interventions and enforcement actions need to be reviewed.

scholarly journals Descriptive Characteristics of Males with Duchenne Muscular Dystrophy in Those Covered by Government (Medicaid) and Non-government (Private) Health Plans

US Neurology ◽  
2018 ◽  
Vol 14 (2) ◽  
pp. 88
Author(s):  
Oscar Henry Mayer ◽  
John Karafilidis ◽  
Kate Higgins ◽  
Brian Griffin ◽  
◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Clinical Characteristics ◽  
International Classification Of Diseases ◽  
Neuromuscular Disorder ◽  
Healthcare Resource Utilization ◽  
Office Visits ◽  
Mechanical Ventilators ◽  
Classification Of Diseases ◽  
Male Patients

Duchenne muscular dystrophy (DMD) is a rare, inherited neuromuscular disorder.Methods:To describe the clinical characteristics and healthcare resource utilization (HCRU) of male patients with DMD in commercial and Medicaid cohorts, this retrospective study identified male patients in the Truven Health MarketScan® Commercial and Medicaid databases diagnosed with hereditary progressive muscular dystrophy (HPMD) presumed to have DMD between 2011–2014. Patients with ≥2 medical claims with a diagnosis for HPMD (International Classification of Diseases, 9th revision, ClinicalModification:359.1) were included. Patients were followed for 12 months after diagnosis date, during which clinical characteristics and HCRU were assessed.Results:In total, 2,285 patients met the selection criteria. In these patients, corticosteroid and anti-infective agents were commonly utilized. Physician office visits were extremely common, with over 70% of all patients having at least one visit. Wheelchairs were commonly used, with the incidence of use increasing with age. Mechanical ventilators and airway clearance devices were underrepresented in the data.Conclusion:Patients with DMD had higher annual HCRU costs when compared with a non-DMD age-matched cohort, with patients in commercial cohorts having a higher annual average cost than those in Medicaid cohorts.

Symptoms and characteristics of cancer patient visits to an emergency room.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18306-e18306
Author(s):  
Michael Gallaway ◽  
Nimi Idaikkadar
Keyword(s):  
Cancer Patients ◽  
Acute Care ◽  
International Classification Of Diseases ◽  
Population Based ◽  
P Value ◽  
Surveillance Program ◽  
Cancer Type ◽  
Classification Of Diseases ◽  
Icd 10 ◽  
Ed Visits

e18306 Background: Cancer patients are increasingly likely to visit an emergency department (ED) for acute care compared to the general population. Cancer patients who visit the ED often have long wait times, increased exposure to infection, and lesser quality treatment. The Centers for Medicare & Medicaid Services (CMS) is encouraging efforts to decrease survivor acute care visits. The purpose of this study was to examine cancer-related ED visits using a national population-based sample to understand why they are seeking care in an ED. Methods: A retrospective cohort study of U.S. patients who visited EDs between June 1, 2017 and May 31, 2018 was conducted using the National Syndromic Surveillance Program (NSSP) BioSense Platform. Cancer patients were identified using International Classification of Diseases, 10th Revision (ICD-10) codes for any cancer type and specifically for cancers of the bladder, female breast, cervix, colon and rectum, kidney, liver, lung, ovary, pancreas, prostate, or uterus. Symptoms were identified using syndromic definitions and key-word queries. Significance testing (p-value ≤0.01), was used to assess differences in the prevalence of symptoms by cancer type. Results: There were 97 million visits to EDs during the study period, 710,297 (0.8%) were among cancer survivors. Slightly more were female (50.1%) than male (49.5%); more were aged 65 or older (53.6%) than 18-64 (1.4-35.3%). The most common symptoms were pain (19%), gastrointestinal (14%), respiratory (12%), neurologic (5%), fever (5%), and injury (4%). Prevalence of symptoms differed significantly by cancer type. Some symptoms were higher among those with specific cancer types compared to all cancers in aggregate: pain (cervical, liver, pancreas); gastrointestinal (pancreas, liver, colorectal); respiratory (lung); neurologic (liver, lung), fever (pancreas, liver), injury (prostate), and bleeding (colorectal, liver). Conclusions: Use of NSSP data enabled a descriptive characterization of more than half of the U.S. ED visits among cancer patients. These comprehensive findings inform best practices to reduce unplanned acute care and help inform possible modifications in treatment and care protocols among survivors of specific cancers.

Abstract 13145: Differences of Cancer Types in Hospital Mortality in Patients With Venous Thromboembolism

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Okushi Yuichiro ◽  
Kenya Kusunose ◽  
Takayuki Ise ◽  
Takeshi Tobiume ◽  
Koji Yamaguchi ◽  
...  
Keyword(s):  
Big Data ◽  
Venous Thromboembolism ◽  
Hospital Mortality ◽  
Cancer Patients ◽  
Biliary Tract ◽  
Gynecological Cancer ◽  
Cancer Type ◽  
Patients With Cancer ◽  
Liver Cancers ◽  
Cancer Types

Introduction: We sought to evaluate the clinical characteristics and outcomes of patients with cancer-associated VTE, compared with the matched cohort without cancer using real-world big data of VTE. Background: Cancer is associated with a high incidence of Venous Thromboembolism (VTE) and there are many guidelines/recommendations about VTE. However, the prognosis of cancer-VTE patients is not well known because of a lack of big data. Moreover, there is also no knowledge on how cancer type is related to prognosis. Methods: This study was based on the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). We identified 28,247 patients who were first hospitalized with VTE from April 2012 to March 2017. 26.0% were cancer patients. Compared with national statistics of cancer incidence in 2015 from National Cancer Center of Japan, the proportion of gynecological cancer patients was higher, but other cancer types had similar prevalence rates. Propensity score (PS) was estimated with logistic regression model, with cancer as the dependent variable and 18 clinically relevant covariates. Results: We included 24,576 patients after exclusion. The median age was 71years (range: 59-80 years), and 42.0% were male. On PS-matched analysis with 12,418 patients, patients with cancer had higher total in-hospital mortality (9.5% vs. 3.8%, P<0.001; OR, 2.72, 95% CI: 2.33-3.19) and in-hospital mortality within 30days (6.8% vs. 3.2%, P<0.001; OR, 2.20, 95% CI: 1.85-2.62). On analysis for each type of cancer, in-hospital mortality in 10 types of cancer was significantly high, especially pancreas (OR: 9.65, 95%CI: 4.31-21.64), biliary tract (OR: 8.36, 95%CI: 2.42-28.89) and liver (OR: 7.33, 95%CI: 1.92-28.02). Conclusions: Patients with cancer had a higher in-hospital mortality for VTE than those without cancer, especially in pancreatic, biliary tract and liver cancers.

scholarly journals Comparison and impact of COVID-19 for patients with cancer: a survival analysis of fatality rate controlling for age, sex and cancer type

2021 ◽  
Vol 28 (1) ◽  
pp. e100341
Author(s):  
Haiquan Li ◽  
Edwin Baldwin ◽  
Xiang Zhang ◽  
Colleen Kenost ◽  
Wenting Luo ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Uterine Cancer ◽  
Fold Increase ◽  
Distant Metastases ◽  
Cancer Type ◽  
Fatality Rate ◽  
Patients With Cancer ◽  
Increased Risk ◽  
Cancer Types ◽  
Stratified Analysis

ObjectivesPrior research has reported an increased risk of fatality for patients with cancer, but most studies investigated the risk by comparing cancer to non-cancer patients among COVID-19 infections, where cancer might have contributed to the increased risk. This study is to understand COVID-19’s imposed HR of fatality while controlling for covariates, such as age, sex, metastasis status and cancer type.MethodsWe conducted survival analyses of 4606 cancer patients with COVID-19 test results from 16 March to 11 October 2020 in UK Biobank and estimated the overall HR of fatality with and without COVID-19 infection. We also examined the HRs of 13 specific cancer types with at least 100 patients using a stratified analysis.ResultsCOVID-19 resulted in an overall HR of 7.76 (95% CI 5.78 to 10.40, p<10−10) by following 4606 patients with cancer for 21 days after the tests. The HR varied among cancer type, with over a 10-fold increase in fatality rate (false discovery rate ≤0.02) for melanoma, haematological malignancies, uterine cancer and kidney cancer. Although COVID-19 imposed a higher risk for localised versus distant metastasis cancers, those of distant metastases yielded higher overall fatality rates due to their multiplicative effects.DiscussionThe results confirmed prior reports for the increased risk of fatality for patients with COVID-19 plus hematological malignancies and demonstrated similar findings of COVID-19 on melanoma, uterine, and kidney cancers.ConclusionThe results highlight the heightened risk that COVID-19 imposes on localised and haematological cancer patients and the necessity to vaccinate uninfected patients with cancer promptly, particularly for the cancer types most influenced by COVID-19. Results also suggest the importance of timely care for patients with localised cancer, whether they are infected by COVID-19 or not.

scholarly journals Deep learning with multimodal representation for pancancer prognosis prediction

2019 ◽  
Vol 35 (14) ◽  
pp. i446-i454 ◽  
Author(s):  
Anika Cheerla ◽  
Olivier Gevaert
Keyword(s):  
Cancer Patients ◽  
Expression Data ◽  
Patient Handling ◽  
Multimodal Data ◽  
Patients With Cancer ◽  
Multiple Data ◽  
Single Feature ◽  
Clinical Methods ◽  
Cancer Types ◽  
Single Cancer

Abstract Motivation Estimating the future course of patients with cancer lesions is invaluable to physicians; however, current clinical methods fail to effectively use the vast amount of multimodal data that is available for cancer patients. To tackle this problem, we constructed a multimodal neural network-based model to predict the survival of patients for 20 different cancer types using clinical data, mRNA expression data, microRNA expression data and histopathology whole slide images (WSIs). We developed an unsupervised encoder to compress these four data modalities into a single feature vector for each patient, handling missing data through a resilient, multimodal dropout method. Encoding methods were tailored to each data type—using deep highway networks to extract features from clinical and genomic data, and convolutional neural networks to extract features from WSIs. Results We used pancancer data to train these feature encodings and predict single cancer and pancancer overall survival, achieving a C-index of 0.78 overall. This work shows that it is possible to build a pancancer model for prognosis that also predicts prognosis in single cancer sites. Furthermore, our model handles multiple data modalities, efficiently analyzes WSIs and represents patient multimodal data flexibly into an unsupervised, informative representation. We thus present a powerful automated tool to accurately determine prognosis, a key step towards personalized treatment for cancer patients. Availability and implementation https://github.com/gevaertlab/MultimodalPrognosis

Sign in / Sign up

Export Citation Format

Share Document